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A Field Day for Gene-Edited Brassicas
and Crop Improvement
Johnathan A. Napier*
A new report in this issue from a U.K. plant science group offers a welcome path forward for crop research
in the field.
Similar to other branches of life sciences, plant research-
ers were quick to recognize the transformative nature of
CRISPR-Cas9–mediated gene editing, and this technol-
ogy (along with its ever-expanding repertoire of variants
and enhancements) has been gleefully embraced by the
international plant sciences community. CRISPR’s flexi-
ble and user-friendly technology is seen as central to ac-
celerating plant breeding and crop improvement, which
in turn will underpin global food security.
In particular, meeting the targets of the United Nations
2015 Sustainable Development Goals—specifically
SDG2’s headline aim of ‘‘zero hunger’’ (or the full goal,
‘‘end hunger, achieve food security and improved nutri-
tion and promote sustainable agriculture’’) by 2030—is
a daunting task that gets harder every day. So, from
one perspective, CRISPR technology could be seen as
arriving just in the nick of time. Certainly, it will play a
vital role in developing new crops that are better adapted
to our changing climates, less impactful on the environ-
ment, and deliver improved nutrition.1
However, although the adoption of CRISPR tools is
now ubiquitous in molecular plant sciences research, pro-
pelling advances in our basic understanding of many as-
pects of crop physiology and stress tolerance, there is still
a gulf between these laboratory-based findings and what
might be termed ‘‘the real world.’’ This is important, be-
cause the closeted research environments we grow our
pampered modified plants in bear no resemblance to the
unpredictable and increasingly variable climates crops
routinely face in the field. Ultimately, if we want our
plant research to lead to some positive societal outcome,
making a contribution to SDG2, then we need to discover
whether genetic changes engineered in the laboratory will
actually work in the field. Will they be robust enough to
continue to deliver benefits, even under a gauntlet of en-
vironmental factors?
For those outside the plant sciences sphere, it might
seem logical if not mandatory for laboratory discoveries
to transition to field evaluation, but this is where wider is-
sues (such as the regulation of transgenic crops) come
into play. These are themselves something of a hot (ge-
netically modified [GM]) potato. And although nowadays
it seems almost obligatory to conclude the write-up of
any new discovery as being a ‘‘game-changer’’ in deliv-
ering food security, etc., in reality, very few fundamental
studies seem prepared to put their money where their (or
others) mouths might be and confirm the potential of their
research by carrying out field trials. This is crucial—you
cannot eat potential!
Now, of course there are many reasons for research not
to transition from the glasshouse to the field, including
less funding for what is still viewed dismissively as ‘‘ap-
plied’’ research, as well as regional differences in how
straightforward (or not) it is to carry out an environmental
release of plants that have been genetically modified.
Moreover, there is a lack of consistency, at least from
various regulatory agencies, as to whether or not genome
editing should be classified as either GM or a form of mu-
tagenesis (or both). This is a particular barrier to transla-
tion in the European Union (EU), which has some of the
least enabling regulations when it comes to genetic mod-
ification. It was surprising and frankly disheartening that
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a review published last year listing all known examples of
genome-editing field trials produced a rather short list,
the bulk of which were run in China on rice.2 Clearly
there is a bottleneck in the translation of much cutting-
edge plant sciences research.
Field Effect
Because of (or perhaps despite) all the mentioned reasons,
a new article by Neequaye et al.3 in Lars Østergaard’s
group at the John Innes Centre, in Norwich, United King-
dom, in this issue of The CRISPR Journal should be
applauded, for the authors have opted to take that road
less traveled and evaluate their CRISPR-Cas9 edited
Brassica oleracea plants in the field.
In this study, Neequaye et al. used gene editing to gen-
erate loss-of-function mutant alleles of the transcription
factor MYB28, which is a key regulator of aliphatic glu-
cosinolate biosynthesis. In doing so, the authors hoped
to change the wider balance of the metabolites present
within the plant, to better understand how to modulate
these health-beneficial compounds without impacting
crop growth. Gene editing in plants can be made more
complicated by both polyploidy and neofunctionaliza-
tion, meaning that the authors had to seek the plants
with useful (disruptive) edits in the different MYB28
paralogues present in B. oleracea. Having identified
mutations in two of the three MYB28 paralogues, the
stage was set for further investigation: at this point, the
study diverges from the majority of CRISPR-mediated
mutagenesis stories by opting to take the evaluation of
the plants into the field.
As noted earlier, environmental release of gene-edited
plants is subject to regulation, the complexity of which is de-
pendent on jurisdiction defined by location (national and re-
gional). In the United Kingdom, a previous field release in
2018 of CRISPR-edited Camelina was classified by the
U.K. regulator as being outside the scope of the European
legal definition of a genetically modified organism, as
such, these plants did not need approval under the mecha-
nism used to approve GM field trials. However, during that
field release in 2018, the European Court of Justice (ECJ)
ruled that gene editing was a form of genetic modification,
at least in the context of the definition first used by the EU
in 2001, eliciting strong reactions from many quarters.4
The ECJ ruling of July 25, 2018, trumped the earlier
U.K. ruling as to the status of gene editing, meaning
that these edited Camelina metaphorically transformed
into GM plants overnight.5 Thus, Neequaye and collea-
gues would need to apply for ‘‘Ministerial consent’’ to
grow their edited B. oleracea plants in the field, since
they were now considered to be GM. This was even
though the authors clearly demonstrated that the trans-
gene carrying the Cas9, gRNAs, and selectable marker
was absent from their plants. All that remained was
the tiny edits in the MYB28 genes that they had
engineered.
FIG. 1. Environmental release and field trialing of GE and GM crops in the United Kingdom. (A) Plots at the
Rothamsted experimental farm of GE, GM, and GE+GM Camelina, June 2020. Note that GE lines are classified as GM
and, as such, are grown within one of the dedicated GM trial areas on the farm. Right panel—large plot of fully
flowering GM Camelina on the Rothamsted experimental farm, June 2018. The profound difference between
controlled glasshouse conditions and those in the field can be exemplified by the variable environmental
conditions and, for example, the presence of insects (B). It is for these reasons it is vital to validate laboratory results






























































For many, obtaining such consent would be viewed as
too cumbersome—the process takes months and requires
mandatory public disclosure of the intention to run a
GM field trial, which can then generate a response from
anti-GM campaign groups. Similarly, there is the obvious
requirement of not only having access to a suitable exper-
imental farm (or similar) but also a commitment to ac-
tually perform experiments in the field, which is quite
different from the pristine laboratory environment (see
Fig. 1 for visual example).
It is to the immense credit of the John Innes group that
they actively embraced the transition from laboratory to
field, validating their hypothesis on the role of MYB28 on
the regulation of glucosinate content in Brassicas, and also
obtaining a comprehensive RNAseq data sets for field-
grown WT and myb28 plants. Perhaps most importantly,
it confirmed the commitment of U.K. plant scientists to con-
tinue to deliver research outcomes that are both academi-
cally exciting and of wider relevance to society.
Although the United Kingdom is currently adhering
to the 2018 ECJ ruling, exit from membership of the
EU in January 2021 presented an opportunity to diverge
from the assertion that gene editing is a form of GM.
To that end, the U.K. government recently concluded a
10-week public consultation on the future regulation of
the new genetic technologies, with the outcome eagerly
awaited this summer.
In the future, studies such as that highlighted here will
hopefully not have so many impediments in the transla-
tion of their fundamental research. By reducing that bur-
den, we might break the bottleneck and see many more
field trials as researchers get to test their innovations in
the real world. This can only be a good thing, especially
if we want to use the phenomenal power of gene editing
to help meet our global challenges.
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CRISPR and Chromothripsis: Proceed with Caution
Stephanie Mack* and I. Alasdair Russell*
A new study in Nature Genetics is a timely reminder of the need to address on- and off-target genome
rearrangements in CRISPR gene editing.
CRISPR-Cas9 has revolutionized all aspects of biology,
making it easier and faster to generate authentic models
of disease through its precise programmable nuclease ac-
tivity. Recently, attention has turned to the clinic, where
the technology is tackling several diseases such as b thal-
assemia and sickle cell disease (SCD).1 As with all ther-
apies, specificity and safety are paramount, and are areas
of intense research.2 To date, most efforts have focused
on spurious editing at unintended sites in the genome. A
wealth of literature is dedicated to identifying3,4 and
mitigating5–10 these off-target edits. Recent observations
have extended spurious editing events to the target site
itself,11 again prompting careful examination of editing
outcome.
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